# Liposomal Bupivacaine (Exparel) in Sarcomas

> **NCT03867188** · EARLY_PHASE1 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 2 (actual)

## Conditions studied

- Soft Tissue Sarcoma
- Soft Tissue Tumor
- Soft Tissue Tumor and/or Sarcoma

## Interventions

- **DRUG:** Liposomal Bupivacaine

## Key facts

- **NCT ID:** NCT03867188
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-14
- **Primary completion:** 2019-06-11
- **Final completion:** 2019-06-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Enrollment of eligible subjects, delays due to the COVID-19 Virus, and lack of funding
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867188, "Liposomal Bupivacaine (Exparel) in Sarcomas". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03867188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*